Boldenone undecylenate is an injectable anabolic steroid originally developed for veterinary use, primarily in horses. It is sold under the brand name Equipoise and is not approved for human medical use. In the United States, it is classified as a Schedule III controlled substance, and it appears on the World Anti-Doping Agency’s prohibited list as a banned anabolic agent.
Chemical Structure and How It Works
Boldenone is a modified form of testosterone. The two molecules are nearly identical, differing by just one extra double bond in the steroid ring structure. That small change alters how the body processes it, giving boldenone a somewhat different balance of muscle-building and masculinizing effects compared to straight testosterone.
The “undecylenate” part of the name refers to a long fatty acid chain attached to the boldenone molecule. This ester acts like a slow-release mechanism: after injection into muscle tissue, the ester gradually breaks off, releasing active boldenone into the bloodstream over days to weeks. In horses, the elimination half-life of boldenone is roughly 123 hours (about 5 days), meaning the drug clears the body slowly and maintains relatively stable blood levels between injections.
Once free in the bloodstream, boldenone works the same way other anabolic steroids do. It enters cells, binds to androgen receptors inside the cell, and that receptor-drug complex travels to the cell nucleus where it interacts with DNA. The end result is increased protein production, particularly in muscle tissue.
Approved Veterinary Uses
Boldenone undecylenate is used in horses to improve nitrogen balance, which is a marker of how efficiently the body builds and retains protein. Veterinarians prescribe it to reduce overexertion from exercise, support appetite, and promote weight gain alongside a balanced diet. It is essentially a recovery and conditioning tool in equine medicine.
Even in horse racing, boldenone is tightly regulated. The Horseracing Integrity and Safety Authority classifies it as a banned substance, with a detection threshold of just 0.015 micrograms per milliliter in urine for male horses. After a single therapeutic injection, boldenone metabolites can be detected in equine urine for up to 42 days.
Why It Has No Approved Human Use
Unlike some anabolic steroids that were developed for human medicine and later repurposed (such as oxandrolone for burn recovery or nandrolone for anemia), boldenone undecylenate was never approved by the FDA for any human condition. It exists in a category of veterinary-only compounds that entered the underground performance-enhancing drug market without ever going through human clinical trials for safety or efficacy.
The Drug Enforcement Administration classifies it as a Schedule III controlled substance alongside other anabolic steroids. Possessing or distributing it without a valid prescription is a federal offense. WADA lists it under category S1 (anabolic agents), making any athlete who tests positive for boldenone or its metabolites subject to a doping violation.
Effects on Blood and Red Blood Cells
One of boldenone’s most notable biological effects is a significant boost in red blood cell production. In controlled animal studies, a single injection increased hematocrit (the percentage of blood volume made up of red blood cells) from about 30% to 35% within two weeks, and from 34% to 42% by the third week. Hemoglobin concentration and total red blood cell count rose in parallel.
This increase in oxygen-carrying capacity is one reason the drug appeals to endurance athletes. More red blood cells means more oxygen delivered to working muscles. But artificially elevated hematocrit also thickens the blood, raising the risk of blood clots, stroke, and cardiovascular events. This is one of the more dangerous physiological consequences of boldenone use.
Liver and Kidney Risks
Research published in Frontiers in Pharmacology found that boldenone undecylenate caused measurable damage to both liver and kidney tissue through a process called oxidative stress, where harmful reactive molecules overwhelm the body’s ability to neutralize them. The drug substantially increased androgen receptor activity in liver and kidney cells, which contributed to cellular degeneration in both organs.
While boldenone is sometimes described in bodybuilding forums as “milder” than other steroids on the liver, the research tells a different story. The activation of androgen receptors in liver cells can trigger a chain of damage that leads to clinical signs of liver toxicity. Kidney tissue shows a similar pattern of increased receptor expression and oxidative damage.
Other Known Side Effects
Because boldenone is structurally so close to testosterone, it carries many of the same risks associated with anabolic steroid use more broadly. These include suppression of the body’s natural testosterone production, which can persist for months after stopping the drug. The body detects the external source of androgens and shuts down its own hormonal signaling in response.
Boldenone can also be partially converted to estrogen in the body, though at a lower rate than testosterone. This means side effects related to elevated estrogen, such as fluid retention and breast tissue growth in men, are possible but generally reported as less common than with testosterone itself. Acne, hair loss in those genetically predisposed, and changes in mood or aggression follow the same pattern seen with other anabolic steroids.
Lipid profiles typically shift in an unfavorable direction with anabolic steroid use. HDL (“good”) cholesterol tends to drop while LDL (“bad”) cholesterol rises, a combination that accelerates plaque buildup in arteries over time. Combined with the blood-thickening effect from increased red blood cell production, this creates a compounding cardiovascular risk that grows with duration of use.
Detection in Drug Testing
Boldenone’s long-acting ester and slow elimination make it one of the more detectable anabolic steroids in anti-doping testing. In horses, metabolites have been confirmed in urine from as early as 2 hours after injection to as long as 42 days later. Human detection windows vary depending on the testing method, but the drug’s slow clearance means traces can persist in urine for weeks to months after the last injection, making it a particularly risky choice for tested athletes.
Modern anti-doping laboratories test for boldenone’s specific metabolites rather than the parent compound. Because boldenone can also be produced in tiny amounts by gut bacteria in some individuals, testing protocols set minimum thresholds to distinguish natural trace levels from intentional use.